Technical Analysis for CHRS - Coherus BioSciences, Inc.

Grade Last Price % Change Price Change
D 1.10 33.90% 0.28
CHRS closed up 33.9 percent on Wednesday, November 20, 2024, on 2.94 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.00%
Expansion Pivot Buy Setup Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Wide Range Bar Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
20 DMA Support Bullish 33.90%
Crossed Above 20 DMA Bullish 40.79%

   Recent Intraday Alerts

Alert Time
Possible Pocket Pivot about 19 hours ago
3x Volume Pace about 21 hours ago
10 DMA Support about 21 hours ago
2x Volume Pace about 21 hours ago
Up 2 ATRs about 21 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Coherus BioSciences, Inc. Description

Coherus Biosciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. Its clinical stage pipeline consists of CHS-0214, an etanercept biosimilar candidate, which is in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420, an adalimumab biosimilar candidate that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701, a pegfilgrastim biosimilar candidate, which has completed a Phase I study for the treatment of breast cancer patients exhibiting chemotherapy-induced neutropenia. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Immunology Breast Cancer Chemotherapy Treatment Of Breast Cancer Psoriasis Rheumatoid Arthritis Immunosuppressants Biosimilar Recombinant Proteins Adalimumab Neutropenia

Is CHRS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.7
52 Week Low 0.6603
Average Volume 3,010,292
200-Day Moving Average 1.67
50-Day Moving Average 0.92
20-Day Moving Average 0.78
10-Day Moving Average 0.82
Average True Range 0.10
RSI (14) 68.94
ADX 23.55
+DI 36.76
-DI 13.30
Chandelier Exit (Long, 3 ATRs) 0.84
Chandelier Exit (Short, 3 ATRs) 0.95
Upper Bollinger Bands 0.95
Lower Bollinger Band 0.61
Percent B (%b) 1.46
BandWidth 42.56
MACD Line -0.01
MACD Signal Line -0.05
MACD Histogram 0.0365
Fundamentals Value
Market Cap 122.5 Million
Num Shares 111 Million
EPS -2.55
Price-to-Earnings (P/E) Ratio -0.43
Price-to-Sales 1.46
Price-to-Book 73.19
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.58
Resistance 3 (R3) 1.54 1.33 1.50
Resistance 2 (R2) 1.33 1.21 1.35 1.47
Resistance 1 (R1) 1.22 1.14 1.27 1.26 1.45
Pivot Point 1.01 1.01 1.04 1.04 1.01
Support 1 (S1) 0.90 0.89 0.96 0.94 0.75
Support 2 (S2) 0.69 0.82 0.72 0.73
Support 3 (S3) 0.58 0.69 0.70
Support 4 (S4) 0.62